CTRVP
What one share of Hepion Pharmaceuticals holds
Pharmaceutical Preparations
Pharmaceuticals, Inc. (we, our, or us) is a medical diagnostic company headquartered in Morristown, New Jersey, that was previously focused on the development of drug therapy for treatment of chronic liver diseases. Our cyclophilin inhibitor, rencofilstat (formerly CRV431), was being developed to offer benefits to address multiple complex pathologies related to the progression of liver disease.
Hepion Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.25 |
|---|---|
| Cash and investments | $0.06 |
| Debt | $0.00 |
| Book value | $0.04 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2018 | — | −$1,391 | — | −$1,216 | — | — |
| 2021 | $0.00 | −$465.52 | $1.86 | −$446.07 | — | $1,220 |
| 2022 | $0.00 | −$594.75 | $0.21 | −$458.85 | — | $654.02 |
| 2023 | $0.00 | −$616.07 | $0.18 | −$515.05 | — | $75.55 |
| 2024 | — | −$107.35 | — | −$148.23 | — | −$13.39 |
| 2025 | — | −$0.88 | — | −$0.35 | — | $0.23 |